Author:
Pietra D,Rumi E,Ferretti V V,Buduo C A Di,Milanesi C,Cavalloni C,Sant'Antonio E,Abbonante V,Moccia F,Casetti I C,Bellini M,Renna M C,Roncoroni E,Fugazza E,Astori C,Boveri E,Rosti V,Barosi G,Balduini A,Cazzola M
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference45 articles.
1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008.
2. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144–1148.
3. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779–1790.
4. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459–468.
5. Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011; 117: 2813–2816.
Cited by
211 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献